Risk factors associated with elevated blood cytomegalovirus pp65 antigen levels in patients with autoimmune diseases

REFERENCES

• Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y, et al. Clinical significance of cytomegalovirus (CMV) antigene-mia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:431–4.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166:1223–7.
   Google Scholar
• Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ. 1973;49:103–6.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063–71.
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalo-virus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2006:CD005133.
   Google Scholar
• Lesprit P, Scieux C, Lemann M, Carbonelle E, Modal J, Molina JM. Use of the cytomegalovirus (CMV) antigenemia assay for the rapid diagnosis of primary CMV infection in hospitalized adults. Clin Infect Dis. 1998;26:646–50.
   PubMed Web of Science ®Google Scholar
• Chevret S, Scieux C, Ganait V, Dahel L, Morinet F, Modal J, et al. Usefulness of the cytomegalovirus (CMV) antigenemia assay for predicting the occurrence of CMV disease and death in patients with AIDS. Clin Infect Dis. 1999;28:758–63.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev. 1998;11:533–54.
   PubMed Web of Science ®Google Scholar
• Tamm M, Traenkle P, Grilli B, Solèr M, Bolliger CT, Dalquen P, et al. Pulmonary cytomegalovirus infection in immunocompro-mised patients. Chest. 2001;119:838–43.
   Google Scholar
• Yoda Y, Hanaoka R, Ide H, Isozaki T, Matsunawa M, Yajima N, et al. Evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia. Mod Rheumatol. 2006;16:137–42.
   PubMedGoogle Scholar
• Hanaoka R, Kurasawa K, Maezawa R, Kumano K, Arai S. Fukuda T. Mod Rheumatol: Reactivation of cytomegalovirus predicts poor prognosis in patients on intensive immunosup-pressive treatment for collagen-vascular diseases; 2011. [Epub ahead of print].
   Google Scholar
• Takizawa Y, Inokuma S, Tanaka Y, Saito K, Atsumi T, Hirakata M, et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient popu-lation. Rheumatology (Oxford). 2008;47:1373–8.
   PubMed Web of Science ®Google Scholar
• Danziger-Isakov L, Mark Baillie G. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant. 2009;23:295–304.
   Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630–40.
   Google Scholar
• Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow trans-plantation. Bone Marrow Transplant. 2000;25:765–9.
   PubMed Web of Science ®Google Scholar
• Fica A, Cervera C, Perez N, Marcos MA, Ramirez J, Linares L, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis. 2007;9:203–10.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: impor-tance of viral load and T-cell immunity. Blood. 2003;101:407–14.
   PubMed Web of Science ®Google Scholar
• Gerard L, Leport C, Flandre P, Houhou N, Salmon-Céron D, Pépin JM, et al. Cytomegalovirus (CMV) viremia and the CD4 + lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;24: 836–40.
   Google Scholar
• Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, et al. Plasma cytomegalovirus DNA, pp65 antigena-emia and a low CD4 cell count remain risk factors for cyto-megalovirus disease in patients receiving highly active antiretroviral therapy. AIDS. 2000;14: 1041–9.
   Google Scholar
• Barber C, Gold WL, Fortin PR. Infections in the lupus patient: perspectives on prevention. Curr Opin Rheumatol. 2011;23:358–65.
   Google Scholar
• Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CG, Abdulahad WH. Disturbed Thl, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol. 2011;141:197–204.
   PubMed Web of Science ®Google Scholar
• Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Ghio M, et al. Impairment of CD8 + T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol. 2001;166:6452–7.
   PubMed Web of Science ®Google Scholar
• Kanetaka Y, Kano Y, Hirahara K, Kurata M, Shiohara T. Rela-tionship between cytomegalovirus reactivation and dermatomy-ositis. Eur J Dermatol. 2011;21:248–53.
   Google Scholar
• Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, et al. Rising pp65 antigenemia during preemptive anticytomeg-alovirus therapy after allogeneic hematopoietic stem cell trans-plantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867–74.
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, Nakagawa M, Kandabashi K, Izutsu K, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36:813–9.
   Google Scholar
• Tnani N, Massoumi A, Lortholary 0, Soussan P, Prinseau J, Baglin A, et al. Management of cytomegalovirus infections in patients treated with immunosuppressive drugs for chronic inflammatory diseases. Rev Med Interne. 2008;29:305–10.
   Google Scholar